Effect of hemodialysis on plasma glucose profile and plasma level of liraglutide in patients with type 2 diabetes mellitus and end-stage renal disease: A pilot study

PLoS ONE

Volumn 9, Issue 12, 2014, Pages

  Osonoi, Takeshi ^a   Saito, Miyoko ^a   Tamasawa, Atsuko ^a   Ishida, Hidenori ^a   Tsujino, Daisuke ^b   Nishimura, Rimei ^b,c   Utsunomiya, Kazunori ^b  

^a Naka Kinen Clinic   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; LIRAGLUTIDE; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL;

AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD GLUCOSE MONITORING; CLINICAL ARTICLE; DISEASE DURATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; END STAGE RENAL DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUCOSE BLOOD LEVEL; HEMODIALYSIS; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; JAPANESE (PEOPLE); MALE; MAXIMUM PLASMA CONCENTRATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PILOT STUDY; TIME TO MAXIMUM PLASMA CONCENTRATION; ADVERSE EFFECTS; BLOOD; CLINICAL TRIAL; COMPLICATION; DIABETES MELLITUS, TYPE 2; KIDNEY FAILURE, CHRONIC; METABOLISM; MIDDLE AGED; RENAL REPLACEMENT THERAPY;

AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY FAILURE, CHRONIC; LIRAGLUTIDE; MALE; MIDDLE AGED; PILOT PROJECTS; RENAL DIALYSIS;

EID: 84919655440     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0113468     Document Type: Article

References (18)

1. Kuriyama S (2001) Dialysis in the diabetic patients. Nursing 21: 82-88 (Japanese only).
2. Abe M, Okada K, Soma M (2011) Antidiabetic agents in patients with chronic kidney disease and endstage renal disease on dialysis: metabolism and clinical practice. Curr Drug Metab 12: 57-69. doi:10.2174/138920011794520053.
3. Nauck M, Frid A, Hermansen K, Thomsen AB, During M, et al. (2013) Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study. Diabetes Obes Metab 15: 204-212. doi:10.1111/dom.12012.
4. Neumiller JJ, Sonnett TE, Wood LD, Setter SM, Campbell RK (2010) Pharmacology, efficacy and safety of liraglutide in the management of type 2 diabetes. Diabetes Metab Syndr Obes 3: 215-226. doi:10.2147/DMSO.S7314.
5. Bode B (2011) Liraglutide: A Review of the First Once-Daily GLP-1 Receptor Agonist. Am J Manag Care 17: S59-S70.
6. Jacobsen LV, Hindsberger C, Robson R, Zdravkovic M (2009) Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide. Br J Clin Pharmacol 68: 898-905. doi:10.1111/j.1365-2125.2009.03536.x.
7. Terawaki Y, Nomiyama T, Akehi Y, Takenoshita H, Nagaishi R, et al. (2013) The efficacy of incretin therapy in patients with type 2 diabetes undergoing hemodialysis. Diabetol Metab Syndr 5: 10. doi:10.1186/1758-5996-5-10.
8. Ministry of Health, Labour and Welfare (1997) ICH E6 (R1) Guideline for Good Clinical Practice 27 March 1997, Ministry of Health, Labour and Welfare.
9. Ministry of Health (2008) Ethical Guidelines for Clinical Studies-Amended 31 July 2008, Ministry of Health, Labour and Welfare, 2008 (Japanese only).
10. World Medical Association (2008) World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects - Last amended by the 59th WMA General Assembly, Seoul 2008. Available: http://www.wma.net/e/policy/b3.htm.
11. Mori Y, Taniguchi Y, Sezaki K, Yokoyama J, Utsunomiya K (2011) Liraglutide narrows the range of circadian glycemic variations in Japanese type 2 diabetes patients and nearly flattens these variations in drug-naive type 2 diabetes patients: a continuous glucose monitoring-based study. Diabetes Technol Ther 13: 1139-1144. doi:10.1089/dia.2011.0137.
12. Mirani M, Berra C, Finazzi S, Calvetta A, Radaelli MG, et al. (2010) Inter-day glycemic variability assessed by continuous glucose monitoring in insulin-treated type 2 diabetes patients on hemodialysis. Diabetes Technol Ther 12: 749-753. doi:10.1089/dia.2010.0052.
13. Krepinsky J, Ingram AJ, Clase CM (2000) Prolonged sulfonylurea-induced hypoglycemia in diabetic patients with end-stage renal disease. Am J Kidney Dis 35: 500-505. doi:10.1016/s0272-6386(00)70204-6.
14. Brock CM (2010) DPP-4 Inhibitors: What Is Their Place in Therapy? US Pharm 35: 8-13.
15. Linnebjerg H, Kothare PA, Park S, Mace K, Reddy S, et al. (2007) Effect of renal impairment on the pharmacokinetics of exenatide. Br J Clin Pharmacol 64: 317-327. doi:10.1111/j.1365-2125.2007.02890.x.
16. Malm-Erjefält M, Bjørnsdottir I, Vanggaard J, Helleberg H, Larsen U, et al. (2010) Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase. Drug Metab Dispos 38: 1944-1953. doi:10.1124/dmd.110.034066.
17. Schmidt WE (2010) Early clinical studies with liraglutide. Int J Clin Pract Suppl 167: 12-20. doi:10.1111/j.1742-1241.2010.02500.x.
18. National Institute for Health and Care Excellence (2010) Diabetes (Type 2)-Liraglutide for the treatment of type-2 diabetes mellitus; NICE technology appraisal guidance 203. October 2010.